Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning

Transfusion and Apheresis Science

Volumn 44, Issue 2, 2011, Pages 205-210

  Servais, Sophie ^a   Baron, Frédéric ^a   Beguin, Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Graft versus host disease; Graft versus tumor effects; Hematopoietic stem cell transplantation; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; MORBIDITY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; REDUCED INTENSITY CONDITIONING;

EID: 79952626837     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2011.01.019     Document Type: Article

References (45)

1. Little M.T., Storb R. History of haematopoietic stem-cell transplantation. Nat. Rev. Cancer 2002, 2:231-238.
2. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 1981, 304:1529-1533.
3. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone-marrow transplantation. Blood 1990, 75:555-562.
4. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
5. Baron F., Petersdorf E.W., Gooley T., et al. What is the role for donor natural killer cells after nonmyeloablative conditioning?. Biol. Blood Marrow Transplant. 2009, 15:580-588.
6. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
7. Nishida T., Hudecek M., Kostic A., et al. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin. Cancer Res. 2009, 15:4759-4768.
8. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
9. Verheyden S., Schots R., Duquet W., Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005, 19:1446-1451.
10. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007, 110:2744-2748.
11. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
12. Baron F., Sandmaier B.M. Nonmyeloablative Transplantation. Hematopoietic Stem Cell Transplantation 2008, 349-374. Humana Press, Totowa. R.J. Soiffer (Ed.).
13. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004, 104:2254-2262.
14. Blaise D., Tabrizi R., Le Corroller A.G., et al. Prospectives randomized comparison of reduced intensity (FLU-BU-ATG), non-myeloablative (FLU-TBI) conditioning for genoidentical allo-SCT: a clinical, economical multicenter ITAC study [abstract]. ASH Annual Meeting Abstracts 2009, 114:193.
15. Mohty M., Labopin M., Janssen J.J.W.M., et al. Comparison of low dose total body irradiation (TBI)-based reduced intensity conditioning (RIC) vs. chemotherapy-based RIC prior to allogeneic stem cell transplantation (allo-SCT) from an HLA identical sibling donor for Acute Myeloid Leukemia (AML) in first complete remission (CR1): a retrospective analysis of 1200 Patients from the Acute Leukemia Working Party of EBMT [abstract]. ASH Annual Meeting Abstracts 2009, 114:1190.
16. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J. Clin. Oncol. 2005, 23:1993-2003.
17. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
18. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
19. Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J. Clin. Oncol. 2008, 26:577-584.
20. Sandmaier B.M., Mackinnon S., Childs R.W. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol. Blood Marrow Transplant. 2007, 13:87-97.
21. Larosa F., Marmier C., Robinet E., et al. Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2005, 35:859-868.
22. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol. Blood Marrow Transplant. 2002, 8:512-520.
23. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
24. Dreger P., Brand R., Milligan D., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005, 19:1029-1033.
25. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
26. Gyurkocza B., Storb R., Storer B.E., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J. Clin. Oncol. 2010, 28:2859-2867.
27. Marks D.I., Wang T., et al. Comparison of outcomes for Non-Myeloablative (NMA) and Myeloablative (MA) conditioning for adults with Acute Lymphoblastic Leukaemia (ALL) in first and second Complete Remission (CR): a Center for International Blood and Marrow Transplant Research (CIBMTR) Analyisis. ASH Annual Meeting Abstracts 2009, 114:872.
28. Laport G.G., Sandmaier B.M., Storer B.E., et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol. Blood Marrow Transplant. 2008, 14:246-255.
29. Kroger N., Holler E., Kobbe G., et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009, 114:5264-5270.
30. Baron F., Storb R., Storer B.E., et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J. Clin. Oncol. 2006, 24:4150-4157.
31. Escalon M.P., Champlin R.E., Saliba R.M., et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J. Clin. Oncol. 2004, 22:2419-2423.
32. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004, 104:3535-3542.
33. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104:3865-3871.
34. Robinson S.P., Sureda A., Canals C., et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009, 94:230-238.
35. Sorror M.L., Storer B.E., Maloney D.G., et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008, 111:446-452.
36. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
37. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N. Engl. J. Med. 2007, 356:1110-1120.
38. Gahrton G., Bjorkstrand B., Iacobelli S., et al. Tandem autologous (ASCT)/Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with identical sibling donor versus ASCT in previously untreated Multiple Myeloma (MM): long term follow up of a prospective controlled trial by the EBMT [abstract]. ASH Annual Meeting Abstracts 2009, 114:52.
39. Baron F., Frere P., Baudoux E., et al. Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update. Haematologica 2003, 88:835-837.
40. Willems E., Baron F., Baudoux E., et al. Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial. Leukemia 2009, 23:608-610.
41. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005, 105:4532-4539.
42. Kohrt H.E., Turnbull B.B., Heydari K., et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009, 114:1099-1109.
43. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
44. Baron F., Lechanteur C., Willems E., et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol. Blood Marrow Transplant. 2010, 16:838-847.
45. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108:1291-1297.